Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years

What are the levels of long-acting injectable-cabotegravir (LAI-CAB) uptake and persistence in the US since Food and Drug Administration approval in December 2021?In this cohort study of national prescription claims from 2022 to 2024, there were 24 194 LAI-CAB users, representing 3% of 781 040 US pre-exposure prophylaxis (PrEP) users. Persistence in LAI-CAB care was 51% in the first year and 23% in the second year; persistence in PrEP care among LAI-CAB users, including oral modalities, was 57% in the first year and 30% in the second year.These findings suggest that LAI-CAB had modest uptake and persistence in care and that structural interventions to facilitate access to highly effective long-acting PrEP modalities are needed.

Corresponding Author: Aaron J. Siegler, PhD, Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Rd, Atlanta, GA 30322 (asiegle@emory.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.